tirzepatide fda approved approval for Zepbound: FSU researcher available for context on newly weight loss treatment Tirzepatide for Weight Loss Receives

Eligibility for medical treatments will be determined by your healthcare provider, who will exercise discretion regarding your treatment plan

Stata software was used for statistical analysis of the outcome measures in all included studies

A medical weight loss program targets the underlying causes of weight gain and obesity so patients can lose weight and keep it off for good

Highlights: GLP-1 receptor agonists linked to 14 percent lower risk of developing substance use disorders Reduced risks observed across alcohol, cannabis, cocaine, nicotine and opioid disorders Patients with existing addiction experienced fewer overdoses, hospitalizations and deaths GLP-1 receptor agonist drugs commonly prescribed for type 2 diabetes mellitus and obesity may also be linked to lower risk of substance use disorders (SUD) , according to a large cohort study published in the journal BMJ (1 Trusted Source Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study